8:00 am Morning Networking Coffee


Grab a quick cup of tea or coffee from the comfort of your own home office and start chatting with your peers in a virtual coffee room.

8:45 am Chair’s Opening Remarks

Does the Choice of Novel Targeted Therapies Best Tailored to the Needs of Patients?

9:00 am Strategies for Overcoming the Immunosuppressive Prostate Tumor Microenvironment

  • Sumit Subudhi Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center

9:30 am Advance the Development of an Epigenetic-based Therapy in Castration-Resistant Prostate Cancer (CRPC)

  • Eric Campeau Senior Director of Translational Medicine, Zenith Epigenetics

10:00 am Investigating CD3 Bispecific Treatment of Solid Tumors using PSMAxCD3

  • Alison Crawford Associate Director of Immuno-Oncology, Regeneron Pharmaceuticals, Inc

10:30 am Morning Break & Virtual Speed Networking


Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange virtual business cards. Form lasting connections through this exclusive virtual speed networking!

11:00 am Optimize Radiopharmaceuticals: Therapy Updates & Development in Prostate Cancer

  • Oliver Sartor Professor of Medicine Medical Director, Tulane Cancer Center & Bernadine Laborde Professor of Cancer Research

11:30 am Spotlight on Veyonda®: Is Noxopharm’s Veyonda the Answer to Safe & Effective Prostate Cancer Treatment?

12:00 pm Bringing Theranostics to Prostate Cancer: A patient centered, safe, and efficient pharmacotherapy

12:30 pm Networking Lunch


• Live Demo in Virtual Exhibition Hall
• 1-1 Meetings

1:30 pm Beyond BRCA: Biomarkers of DNA Damage Response Deficiency (DDR-D)

  • Patrick Pilié Assistant Professor GU Medical Oncology, MD Anderson Cancer Center

2:00 pm PSMA-ATAC: Introducing a Novel Mode of Action into Prostate Cancer Therapy

Stronger together:
Navigating Through the Plethora of Combinatorial Therapies

2:30 pm Chemotherapy & Chemotherapy Combinations – Is there Still a Role in Prostate Cancer?

  • Ana Aparicio Associate Professor & Director Clinical Research Group, University of Texas, MD Anderson Cancer Center

3:00 pm Afternoon Break


• Live Demo in Virtual Exhibition Hall
• 1-1 Meetings

3:30 pm Targeting Treatment Emergent Genomic Alterations & Tumor Plasticity

4:00 pm Panel Discussion: Evaluate the Current Challenges, Approaches & Opportunities in Treating Prostate Cancer

  • Ramesh Narayanan Professor of the Department of Medicine & Director of Center for Cancer Drug Discovery, University of Tennessee Health Science Center
  • Alessandra Cesano Chief Medical Officer, ESSA Pharmaceuticals
  • Graham Kelly Chief Executive Officer & Founder, Noxopharm
  • Vivek Arora Director, Translational Medicine,Early Clinical Development, Hematology/ Oncology & Cell Therapy, Bristol-Myers Squibb (BMS)

4:45 pm Chair Closing Remarks